Michael E. Wechsler

23.4k total citations · 10 hit papers
193 papers, 9.2k citations indexed

About

Michael E. Wechsler is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Rheumatology. According to data from OpenAlex, Michael E. Wechsler has authored 193 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 122 papers in Physiology, 97 papers in Pulmonary and Respiratory Medicine and 50 papers in Rheumatology. Recurrent topics in Michael E. Wechsler's work include Asthma and respiratory diseases (119 papers), Respiratory and Cough-Related Research (48 papers) and Eosinophilic Disorders and Syndromes (45 papers). Michael E. Wechsler is often cited by papers focused on Asthma and respiratory diseases (119 papers), Respiratory and Cough-Related Research (48 papers) and Eosinophilic Disorders and Syndromes (45 papers). Michael E. Wechsler collaborates with scholars based in United States, United Kingdom and France. Michael E. Wechsler's co-authors include Elliot Israel, Mario Castro, Amy D. Klion, James Zangrilli, Jorge Máspero, Andrew Menzies‐Gow, Jason T. Olin, Gerald J. Gleich, Stephanie Korn and Guy Brusselle and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Michael E. Wechsler

182 papers receiving 9.0k citations

Hit Papers

Reslizumab for inadequately controlled asthma with elevat... 2015 2026 2018 2022 2015 2021 2017 2021 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
    2015 840 citations Mario Castro, Michael E. Wechsler et al. profile →
  2. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
    2021 606 citations Arnaud Bourdin, Geoffrey Chupp et al. New England Journal of Medicine profile →
  3. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
    2017 589 citations Michael E. Wechsler, Peter A. Merkel et al. New England Journal of Medicine profile →
  4. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
    2021 258 citations Michael E. Wechsler, Ian Pavord et al. New England Journal of Medicine profile →
  5. Sex and gender in asthma
    2021 236 citations Michael E. Wechsler et al. profile →
  6. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial
    2021 225 citations Michael E. Wechsler, Christopher E. Brightling et al. profile →
  7. Eosinophils in Health and Disease: A State-of-the-Art Review
    2021 164 citations Michael E. Wechsler, Ariel Munitz et al. Mayo Clinic Proceedings profile →
  8. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis
    2022 146 citations Michael E. Wechsler, Parameswaran Nair et al. The Journal of Allergy and Clinical Immunology In Practice profile →
  9. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
    2024 69 citations Michael E. Wechsler, Parameswaran Nair et al. New England Journal of Medicine profile →
  10. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
    2024 47 citations David J. Jackson, Michael E. Wechsler et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael E. Wechsler United States 49 5.9k 5.0k 2.0k 1.8k 1.7k 193 9.2k
Elisabeth H. Bel Netherlands 56 9.9k 1.7× 8.2k 1.6× 330 0.2× 1.6k 0.9× 1.2k 0.7× 162 12.3k
César Picado Spain 49 4.4k 0.8× 2.8k 0.6× 619 0.3× 784 0.4× 1.2k 0.7× 329 8.6k
E. Rand Sutherland United States 36 4.6k 0.8× 3.3k 0.6× 215 0.1× 1.3k 0.7× 620 0.4× 62 6.6k
Theodore F. Reiss United States 41 4.9k 0.8× 3.7k 0.7× 288 0.1× 320 0.2× 1.3k 0.7× 105 8.9k
Wendy C. Moore United States 39 4.1k 0.7× 3.0k 0.6× 165 0.1× 1.4k 0.8× 689 0.4× 98 5.5k
Jacob K. Sont Netherlands 39 3.2k 0.5× 3.1k 0.6× 243 0.1× 550 0.3× 298 0.2× 138 5.3k
Dario Olivieri Italy 40 3.2k 0.5× 4.2k 0.8× 174 0.1× 554 0.3× 417 0.2× 156 6.1k
Anne E. Tattersfield United Kingdom 43 5.1k 0.9× 4.5k 0.9× 235 0.1× 252 0.1× 321 0.2× 100 7.1k
Masakazu Ichinose Japan 45 3.3k 0.6× 4.0k 0.8× 113 0.1× 842 0.5× 509 0.3× 261 7.3k
Kelan G. Tantisira United States 46 3.7k 0.6× 2.4k 0.5× 80 0.0× 1.1k 0.6× 711 0.4× 191 6.5k

Countries citing papers authored by Michael E. Wechsler

Since Specialization
Citations

This map shows the geographic impact of Michael E. Wechsler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Wechsler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Wechsler more than expected).

Fields of papers citing papers by Michael E. Wechsler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Wechsler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Wechsler. The network helps show where Michael E. Wechsler may publish in the future.

Co-authorship network of co-authors of Michael E. Wechsler

This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Wechsler. A scholar is included among the top collaborators of Michael E. Wechsler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Wechsler. Michael E. Wechsler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nanzer, Alexandra M., et al.. (2026). Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA): Do We Need Immunosuppressives?. The Journal of Allergy and Clinical Immunology In Practice. 14(3). 613–618.
2.
Busse, William W., Ian Pavord, Michael E. Wechsler, et al.. (2025). Reduction in the Use of Rescue Medication for Asthma Symptom Relief With Rilzabrutinib: Results from a Phase 2 Study. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A1298–A1298. 1 indexed citations
3.
Wechsler, Michael E., et al.. (2025). Asthma therapeutics: Past, present, and future. Pharmacological Reviews. 77(4). 100062–100062.
4.
Wechsler, Michael E., et al.. (2024). Novel asthma treatments. Annals of Allergy Asthma & Immunology. 134(1). 9–18. 10 indexed citations
5.
Wechsler, Michael E., et al.. (2024). Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATION. The Journal of Allergy and Clinical Immunology In Practice. 12(11). 3128–3131.e2. 3 indexed citations
6.
Boulet, Louis‐Philippe, Carl Abbott, Guy Brusselle, et al.. (2024). Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study. The Journal of Allergy and Clinical Immunology In Practice. 12(5). 1244–1253.e8. 2 indexed citations
7.
Jackson, David J., Michael E. Wechsler, Daniel J. Jackson, et al.. (2024). Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. New England Journal of Medicine. 391(24). 2337–2349. 47 indexed citations breakdown →
8.
Wechsler, Michael E., et al.. (2024). Use of Biologics and Asthma Remission in Underrepresented Patient Populations. A5370–A5370. 1 indexed citations
9.
Wechsler, Michael E., Parameswaran Nair, Benjamin Terrier, et al.. (2024). Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine. 390(10). 911–921. 69 indexed citations breakdown →
10.
Couillard, Simon, David J. Jackson, Ian Pavord, & Michael E. Wechsler. (2024). Choosing the Right Biologic for the Right Patient With Severe Asthma. CHEST Journal. 167(2). 330–342. 14 indexed citations
11.
Wechsler, Michael E., Guy Brusselle, J. Christian Virchow, et al.. (2024). Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies. European Respiratory Journal. 64(6). 2400316–2400316. 19 indexed citations
12.
Carr, Tara F., Wendy C. Moore, Monica Kraft, et al.. (2024). Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study. Advances in Therapy. 41(7). 2978–2990. 10 indexed citations
13.
Domingo, Christian, Klaus F. Rabe, David Price, et al.. (2023). Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose. ERJ Open Research. 9(6). 56–2023. 4 indexed citations
14.
Mosnaim, Giselle, Flavia Hoyte, Guilherme Safioti, et al.. (2023). Effectiveness of a Maintenance and Reliever Digihaler System in Asthma: 24-Week Randomized Study (CONNECT2). The Journal of Allergy and Clinical Immunology In Practice. 12(2). 385–395.e4. 19 indexed citations
15.
Wechsler, Michael E., Ariel Munitz, Steven J. Ackerman, et al.. (2021). Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clinic Proceedings. 96(10). 2694–2707. 164 indexed citations breakdown →
16.
Kerkhof, Marjan, Trung N. Tran, Riyad Al‐Lehebi, et al.. (2021). Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities. The Journal of Allergy and Clinical Immunology In Practice. 9(12). 4353–4370. 12 indexed citations
17.
Georas, Steve N., et al.. (2021). JAK inhibitors for asthma. Journal of Allergy and Clinical Immunology. 148(4). 953–963. 64 indexed citations
18.
Grossman, N., Gheorghe Doros, Anne L. Fuhlbrigge, et al.. (2018). Susceptibility to exacerbations in Black adults with asthma. Journal of Asthma. 56(7). 704–710. 2 indexed citations
19.
Birben, Esra, Cansın Saçkesen, Shamsah Kazani, et al.. (2011). The effects of an insertion in the 5′UTR of the AMCase on gene expression and pulmonary functions. Respiratory Medicine. 105(8). 1160–1169. 4 indexed citations
20.
Wechsler, Michael E., Hartmut Grasemann, Aaron Deykin, et al.. (2000). Exhaled Nitric Oxide in Patients with Asthma. American Journal of Respiratory and Critical Care Medicine. 162(6). 2043–2047. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisabeth H. Bel Breakdown of academic impact, for papers by César Picado Breakdown of academic impact, for papers by E. Rand Sutherland Breakdown of academic impact, for papers by Theodore F. Reiss Breakdown of academic impact, for papers by Wendy C. Moore Breakdown of academic impact, for papers by Jacob K. Sont Breakdown of academic impact, for papers by Dario Olivieri Breakdown of academic impact, for papers by Anne E. Tattersfield Breakdown of academic impact, for papers by Masakazu Ichinose Breakdown of academic impact, for papers by Kelan G. Tantisira
Rankless by CCL
2026